TDMS No. 99024 - 07		P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)	Date Report Requested: 08/08/2008
Test Type: CHRONIC		Androstenedione	Time Report Requested: 08:20:33
Route: GAVAGE		CAS Number: 63-05-8	First Dose M/F: 02/03/03 / 02/03/03
Species/Strain: RATS/F 344			Lab: SRI
		F1_R2	
C Number:	C99024C		

Lock Date:	06/29/2006
Cage Range:	ALL
Date Range:	ALL
Reasons For Removal:	ALL
Removal Date Range:	ALL
Treatment Groups:	Include ALL
Study Gender:	Both
TDMSE Version:	2.0.0

### Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG
Disposition Summary				
Animals Initially in Study	50	50	50	50
Early Deaths	22	2	47	10
Moribund Sacrifice Natural Death	22 7	9 8	17 4	13 10
Survivors	7	8	4	10
Natural Death	1			
Terminal Sacrifice	20	33	29	27
Animals Examined Microscopically	50	50	50	50
ALIMENTARY SYSTEM				
Esophagus	(50)	(50)	(50)	(50)
Foreign Body	1 (2%)	(00)	(00)	(00)
Inflammation, Suppurative	1 (2%)			
Intestine Large, Cecum	(47)	(46)	(47)	(48)
Edema	、 <i>,</i>	. ,	1 (2%)	. /
Intestine Large, Colon	(44)	(43)	(47)	(44)
Edema	2 (5%)	1 (2%)	4 (9%)	
Fibrosis	1 (2%)	( )	( )	
Intestine Large, Rectum	(46)	(46)	(47)	(47)
Hemorrhage	(40)	(47)	1 (2%)	(47)
Intestine Small, Duodenum Hemorrhage	(48)	(47)	(49)	(47)
Intestine Small, Ileum	(44)	(46)	1 (2%) (47)	(44)
Intestine Small, Jejunum	(44)	(40) (44)	(47)	(42)
Hemorrhage	(44)	(++)	1 (2%)	(+2)
Liver	(50)	(50)	(50)	(50)
Angiectasis	(00)	1 (2%)	(30)	1 (2%)
Basophilic Focus	17 (34%)	29 (58%)	29 (58%)	33 (66%)
Clear Cell Focus	13 (26%)	21 (42%)	23 (46%)	14 (28%)
Clear Cell Focus, Multiple				3 (6%)
Degeneration, Cystic	10 (20%)	3 (6%)	12 (24%)	7 (14%)
Eosinophilic Focus	3 (6%)	10 (20%)	7 (14%)	13 (26%)
Hematopoietic Cell Proliferation		1 (2%)		
Hemorrhage			1 (2%)	
Hepatodiaphragmatic Nodule	7 (14%)	8 (16%)	7 (14%)	10 (20%)
Infiltration Cellular, Mixed Cell	10 (20%)	3 (6%)	11 (22%)	4 (8%)
Inflammation, Chronic	1 (2%)	O(40)	4 (00())	4 (00()
Mixed Cell Focus	1 (2%)	2 (4%)	1 (2%)	4 (8%)
Necrosis, Focal	4 (8%) 1 (2%)		1 (2%)	1 (2%)
Tension Lipidosis	1 (2%)			

### Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

#### CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
Thrombosis			1 (2%)		
Bile Duct, Hyperplasia	44 (88%)	44 (88%)	40 (80%)	43 (86%)	
Hepatocyte, Hyperplasia	1 (2%)		2 (4%)	2 (4%)	
Hepatocyte, Vacuolization Cytoplasmic	25 (50%)	18 (36%)	14 (28%)	9 (18%)	
Kupffer Cell, Pigmentation	1 (2%)			. ,	
Mesentery	(18)	(13)	(12)	(18)	
Accessory Spleen	4 (22%)	1 (8%)		3 (17%)	
Hemorrhage		1 (8%)			
Inflammation, Suppurative	1 (6%)				
Inflammation, Granulomatous	1 (6%)				
Fat, Necrosis	13 (72%)	10 (77%)	10 (83%)	15 (83%)	
Pancreas	(50)	(50)	(50)	(50)	
Atrophy	17 (34%)	30 (60%)	19 (38%)	21 (42%)	
Cyst	5 (10%)	3 (6%)	7 (14%)		
Infiltration Cellular, Lymphocyte				1 (2%)	
Acinus, Cytoplasmic Alteration	4 (8%)	3 (6%)	2 (4%)	2 (4%)	
Acinus, Hyperplasia, Focal	1 (2%)	3 (6%)	3 (6%)	2 (4%)	
Arteriole, Inflammation, Chronic		1 (2%)			
Salivary Glands	(50)	(50)	(50)	(50)	
Atrophy				1 (2%)	
Stomach, Forestomach	(50)	(50)	(50)	(50)	
Edema	4 (8%)	7 (14%)	4 (8%)	4 (8%)	
Erosion	1 (2%)				
Hemorrhage			1 (2%)		
Inflammation, Chronic Active		1 (2%)			
Ulcer	6 (12%)	7 (14%)	4 (8%)	5 (10%)	
Epithelium, Hyperplasia	5 (10%)	6 (12%)	3 (6%)	5 (10%)	
Stomach, Glandular	(50)	(50)	(50)	(50)	
Edema				1 (2%)	
Erosion	6 (12%)	2 (4%)	4 (8%)	5 (10%)	
Ulcer	2 (4%)	1 (2%)	2 (4%)	1 (2%)	
Epithelium, Cyst	1 (2%)			1 (2%)	
Epithelium, Hyperplasia	1 (2%)		2 (4%)	2 (4%)	
_ Muscularis, Hyperplasia	<i>(</i> )	4-3	(-)	1 (2%)	
Tongue	(1)	(0)	(0)	(2)	
Hyperplasia, Squamous	4-3	4-3		2 (100%)	
Tooth	(0)	(0)	(1)	(0)	
Malformation			1 (100%)		
CARDIOVASCULAR SYSTEM					
Blood Vessel	(2)	(3)	(1)	(0)	
Heart	(50)	(50)	(50)	(50)	
Cardiomyopathy	47 (94%)	47 (94%)	48 (96%)	48 (96%)	
Thrombosis	6 (12%)	3 (6%)	3 (6%)	2 (4%)	
	· · /	· · /			

Route: GAVAGE

# Test Type: CHRONIC

Species/Strain: RATS/F 344

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

#### **CAS Number:** 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
ENDOCRINE SYSTEM					
Adrenal Cortex	(50)	(50)	(50)	(50)	
Accessory Adrenal Cortical Nodule	(50) 1 (2%)	(50) 3 (6%)	(50) 1 (2%)	(50) 1 (2%)	
				21 (42%)	
Degeneration, Fatty Hyperplasia, Focal	22 (44%) 5 (10%)	27 (54%) 4 (8%)	25 (50%) 3 (6%)	1 (2%)	
				1 (2%)	
Hypertrophy, Focal	3 (6%)	3 (6%)	2 (4%)	4 (8%)	
Hypertrophy, Diffuse	4 (00()			1 (2%)	
Necrosis	1 (2%)	4 (00()			
Bilateral, Necrosis	(50)	1 (2%)	(50)	(50)	
Adrenal Medulla	(50)	(50)	(50)	(50)	
Hyperplasia	5 (10%)	8 (16%)	6 (12%)	10 (20%)	
Infiltration Cellular, Lymphocyte	(50)	(50)	(50)	1 (2%)	
Islets, Pancreatic	(50)	(50)	(50)	(50)	
Hyperplasia	5 (10%)	4 (8%)	2 (4%)	9 (18%)	
Parathyroid Gland	(48)	(50)	(50)	(48)	
Cyst		1 (2%)		( ( 2 ) )	
Hyperplasia	(50)	(50)	(10)	1 (2%)	
Pituitary Gland	(50)	(50)	(49)	(50)	
Pars Distalis, Angiectasis	1 (2%)	1 (2%)		2 (4%)	
Pars Distalis, Cyst	2 (4%)	3 (6%)	1 (2%)	4 (8%)	
Pars Distalis, Hyperplasia, Focal	13 (26%)	15 (30%)	21 (43%)	18 (36%)	
Pars Intermedia, Angiectasis				1 (2%)	
Pars Intermedia, Cyst			2 (4%)		
Pars Intermedia, Hyperplasia, Focal			1 (2%)		
Rathke's Cleft, Cyst			1 (2%)		
Thyroid Gland	(50)	(50)	(50)	(50)	
Ultimobranchial Cyst	1 (2%)	1 (2%)	2 (4%)		
C-cell, Hyperplasia	32 (64%)	33 (66%)	26 (52%)	20 (40%)	
Follicle, Cyst		1 (2%)	5 (10%)	1 (2%)	
Follicular Ċell, Hyperplasia		2 (4%)	2 (4%)	1 (2%)	
GENERAL BODY SYSTEM					
Tissue NOS	(0)	(0)	(1)	(0)	
GENITAL SYSTEM					
Coogulating Cland	(0)	(2)	(0)	(0)	
Coagulating Gland	(0)	(3)	(2)	(0)	
Inflammation, Suppurative		1 (33%)			
Epithelium, Hyperplasia	(50)	1 (33%)	(50)	(50)	
Epididymis	(50)	(50)	(50)	(50)	

# Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

#### CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
Atrophy	1 (2%)				
Degeneration	1 (2%)				
Inflammation, Chronic				1 (2%)	
Penis	(0)	(1)	(0)	(0)	
Inflammation, Chronic	(50)	1 (100%)	(50)	(50)	
Preputial Gland	(50)	(50)	(50)	(50)	
Cyst Fibrosis	4 (8%)	2 (4%)		7 (14%) 1 (2%)	
Hyperplasia	1 (2%)	1 (2%)		1 (2%)	
Inflammation, Chronic	47 (94%)	48 (96%)	41 (82%)	43 (86%)	
Prostate	(50)	(50)	(50)	(50)	
Inflammation, Chronic	25 (50%)	24 (48%)	20 (40%)	20 (40%)	
Epithelium, Hyperplasia	9 (18%)	18 (36%)	9 (18%)	12 (24%)	
Seminal Vesicle	(50)	(50)	(50)	(50)	
Testes	(50)	(50)	(50)	(50)	
Malformation				1 (2%)	
Thrombosis	1 (2%)				
Germinal Epithelium, Atrophy	9 (18%)	8 (16%)	10 (20%)	11 (22%)	
Interstitial Cell, Hyperplasia	4 (8%)	2 (4%)	2 (4%)	2 (4%)	
HEMATOPOIETIC SYSTEM Bone Marrow	(50)	(50)	(50)	(50)	
Hyperplasia	4 (8%)	4 (8%)	4 (8%)	7 (14%)	
Myelofibrosis	1 (2%)	2 (4%)			
Lymph Node	(25)	(18)	(16)	(13)	
Mediastinal, Angiectasis		1 (6%)			
Mediastinal, Ectasia	1 (4%)		2 (13%)		
Mediastinal, Fibrosis	1 (4%)	4 (00()	4 (00()		
Mediastinal, Hemorrhage Mediastinal, Hyperplasia, Histiocytic	4 (40/)	1 (6%)	1 (6%)		
Mediastinal, Hyperplasia, Histocytic Mediastinal, Hyperplasia, Lymphoid	1 (4%) 3 (12%)	3 (17%)			
Pancreatic, Angiectasis	3 (12%)	3 (1776)		1 (8%)	
Pancreatic, Atrophy	1 (4%)			1 (0 %)	
Pancreatic, Ectasia	3 (12%)	1 (6%)	2 (13%)		
Pancreatic, Hemorrhage	1 (4%)	. (0,0)	1 (6%)		
Pancreatic, Hyperplasia, Histiocytic	7 (28%)		3 (19%)	2 (15%)	
Pancreatic, Hyperplasia, Lymphoid	1 (4%)		· · /	· · · ·	
Pancreatic, Necrosis		1 (6%)			
Lymph Node, Mandibular	(1)	(0)	(1)	(2)	
Lymph Node, Mesenteric	(50)	(50)	(50)	(50)	
Atrophy	1 (2%)	= (( 22()	- (( (a))	- (( ( )	
Ectasia	3 (6%)	5 (10%)	7 (14%)	5 (10%)	
Fibrosis	1 (2%)		2(40/)		
Hemorrhage			2 (4%)		

### Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

#### CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
Hyperplasia, Histiocytic Hyperplasia, Lymphoid Infiltration Cellular, Eosinophil Infiltration Cellular, Plasma Cell	25 (50%) 1 (2%) 1 (2%) 1 (2%)	13 (26%) 2 (4%)	25 (50%) 1 (2%)	19 (38%) 1 (2%)	
Pigmentation Spleen Accessory Spleen Fibrosis	(50) 6 (12%)	(50) 1 (2%) 1 (2%)	(50) 1 (2%) 4 (8%)	2 (4%) (50)	
Hematopoietic Cell Proliferation Hemorrhage Hyperplasia, Histiocytic Hyperplasia, Lymphoid	2 (4%) 2 (4%) 1 (2%) 1 (2%)		4 (8%)	2 (4%) 1 (2%)	
Necrosis Pigmentation Lymphoid Follicle, Hyperplasia Red Pulp, Hyperplasia	2 (4%) 12 (24%)	1 (2%) 12 (24%) 3 (6%)	1 (2%) 8 (16%) 4 (8%) 1 (2%)	12 (24%) 3 (6%)	
Thymus Atrophy Cyst Hemorrhage	(50)	(50) 1 (2%)	(50) 2 (4%) 1 (2%) 1 (2%)	(49)	
Hyperplasia, Lymphoid	2 (4%)	1 (270)	1 (270)		
INTEGUMENTARY SYSTEM					
Mammary Gland Cyst Hyperplasia Inflammation, Granulomatous	(48) 8 (17%) 38 (79%) 1 (2%)	(50) 4 (8%) 37 (74%)	(50) 4 (8%) 33 (66%)	(50) 11 (22%) 42 (84%)	
Skin Cyst Epithelial Inclusion Fibrosis	(50) 3 (6%)	(50) 1 (2%) 2 (4%) 3 (6%)	(50) 1 (2%) 1 (2%) 6 (12%)	(50) 2 (4%) 3 (6%) 7 (14%)	
Hyperkeratosis Inflammation, Suppurative Inflammation, Granulomatous Inflammation, Chronic	5 (10%)	3 (0%)	6 (12%) 1 (2%)	1 (2%) 1 (2%) 1 (2%) 1 (2%)	
Ulcer Epidermis, Hyperplasia	3 (6%)	1 (2%)	3 (6%)	1 (2%) 3 (6%)	
MUSCULOSKELETAL SYSTEM					
Bone Cranium, Osteopetrosis Skeletal Muscle Fibrosis	(50) 1 (2%) (8) 3 (38%)	(50) (1)	(50) (3) 2 (67%)	(50) 1 (2%) (5) 1 (20%)	

# Test Type: CHRONIC

Species/Strain: RATS/F 344

Route: GAVAGE

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
ERVOUS SYSTEM					
Brain Compression	(50) 13 (26%)	(50) 8 (16%)	(50) 7 (14%)	(50) 9 (18%)	
Gliosis	1 (2%)	0 (1070)			
Hemorrhage	3 (6%)		2 (4%)	4 (8%)	
Necrosis Spinal Cord	(6)	(1)	(0)	2 (4%) (5)	
	(0)	(1)	(0)	(3)	
ESPIRATORY SYSTEM					
Lung	(50)	(50)	(50)	(50)	
Congestion			1 (2%)		
Foreign Body	4 (00/)	4 (00()	1 (2%)	4 (00()	
Hemorrhage	1 (2%)	1 (2%)	1 (2%)	1 (2%)	
Infiltration Cellular, Histiocyte	17 (34%)	17 (34%)	18 (36%) 1 (2%)	18 (36%)	
Inflammation, Granulomatous Inflammation, Chronic		1 (2%)	1 (2%)	1 (2%) 3 (6%)	
Metaplasia, Osseous		1 (2%)	1 (2%)	3 (0%)	
Alveolar Epithelium, Hyperplasia	6 (12%)	7 (14%)	8 (16%)	4 (8%)	
Serosa, Cyst	0 (12%)	7 (14%)	8 (10%)	4 (8%) 1 (2%)	
Nose	(50)	(50)	(50)	(50)	
Foreign Body	5 (10%)	13 (26%)	5 (10%)	(30)	
Infiltration Cellular, Lymphocyte	3 (10%)	13 (2070)	1 (2%)		
Inflammation, Suppurative	3 (6%)	4 (8%)	1 (2%)	1 (2%)	
Inflammation, Chronic	4 (8%)	3 (6%)	5 (10%)	1 (2%)	
Nasolacrimal Duct, Inflammation, Chronic	(()))	- ( )		1 (2%)	
Respiratory Epithelium, Hyperplasia	8 (16%)	11 (22%)	7 (14%)	3 (6%)	
Sinus, Inflammation, Suppurative	1 (2%)	( ),	( )		
Vomeronasal Organ, Atrophy			1 (2%)		
PECIAL SENSES SYSTEM					
Eye	(48)	(46)	(50)	(49)	
Cataract	1 (2%)		1 (2%)	2 (4%)	
Ciliary Body, Hyperplasia	1 (2%)		. (-,-,	- ( /	
Retina, Degeneration	1 (2%)	1 (2%)	1 (2%)	4 (8%)	
Retina, Edema	· · · /			1 (2%)	
Sclera, Metaplasia, Osseous		3 (7%)	2 (4%)	1 (2%)	
Harderian Gland	(50)	(50)	(50)	(50)	
Infiltration Cellular, Lymphocyte Inflammation, Chronic			1 (2%)	1 (2%)	

# Test Type: CHRONIC

#### Route: GAVAGE

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

#### CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS MALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
Necrosis Zymbal's Gland	1 (2%) (0)	(0)	(1)	(0)	
JRINARY SYSTEM					
Kidney Cyst Hydronephrosis Infarct	(49) 3 (6%)	(50) 1 (2%)	(50)	(50) 1 (2%) 1 (2%)	
Nephropathy Renal Tubule, Accumulation, Hyaline Droplet Renal Tubule, Necrosis	42 (86%) 1 (2%) 1 (2%)	48 (96%) 1 (2%) 1 (2%)	46 (92%) 2 (4%)	44 (88%) 1 (2%)	
Renal Tubule, Pigmentation Urinary Bladder Calculus Micro Observation Only	5 (10%) (50)	2 (4%) (50) 1 (2%)	6 (12%) (50)	6 (12%) (50)	
Hemorrhage Inflammation, Chronic Transitional Epithelium, Hyperplasia		1 (2%) 2 (4%)		1 (2%)	

\*\*\* END OF MALE \*\*\*

### Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
isposition Summary					
Animals Initially in Study	50	50	50	50	
Early Deaths		_	10		
Moribund Sacrifice	10	7	12	9	
Natural Death	2	6	5	4	
Survivors		4			
Natural Death Terminal Sacrifice	38	1 36	33	37	
Animals Examined Microscopically	38 50	30 50	50	50	
	30	30	30	30	
LIMENTARY SYSTEM					
Intestine Large, Rectum	(49)	(47)	(47)	(48)	
Edema	1 (2%)				
Intestine Small, Ileum	(48)	(46)	(45)	(48)	
Serosa, Inflammation, Chronic	1 (2%)				
Liver	(50)	(50)	(50)	(50)	
Angiectasis	/	1 (2%)		1 (2%)	
Basophilic Focus	47 (94%)	46 (92%)	42 (84%)	38 (76%)	
Clear Cell Focus	14 (28%)	10 (20%)	11 (22%)	14 (28%)	
Degeneration, Cystic	- (( ( )			1 (2%)	
Eosinophilic Focus	5 (10%)	4 (22()	4 (8%)		
Fibrosis	1 (2%)	1 (2%)			
Hematopoietic Cell Proliferation	1 (2%)			4 (00()	
Hemorrhage	10 (20%)	9 (18%)	11 (22%)	1 (2%)	
Hepatodiaphragmatic Nodule Infiltration Cellular, Mixed Cell				9 (18%)	
Mixed Cell Focus	21 (42%) 1 (2%)	33 (66%)	32 (64%) 2 (4%)	31 (62%)	
Necrosis, Focal	I (270)		2 (4%) 1 (2%)	1 (2%)	
Bile Duct, Hyperplasia	12 (24%)	16 (32%)	18 (36%)	24 (48%)	
Centrilobular, Necrosis	12 (27/0)	10 (02 /0)	10 (0070)	1 (2%)	
Hepatocyte, Vacuolization Cytoplasmic	6 (12%)	4 (8%)	7 (14%)	5 (10%)	
Kupffer Cell, Pigmentation	2 (4%)	. (676)	, (17/0)	0 (10,0)	
Mesentery	(13)	(14)	(15)	(15)	
Accessory Spleen	2 (15%)	( )	3 (20%)	2 (13%)	
Fat, Necrosis	12 (92%)	14 (100%)	14 (93%)	12 (80%)	
Oral Mucosa	(0)	(1)	(0)	(0)	
Pancreas	(50)	(ŠÓ)	(50)	(50)	
Atrophy	10 (20%)	10 (20%)	16 (32%)	26 (52%)	
Cyst	3 (6%)	7 (14%)	4 (8%)	2 (4%)	
Infiltration Cellular, Lymphocyte			1 (2%)	3 (6%)	
Acinus, Cytoplasmic Alteration		4 (8%)	1 (2%)	2 (4%)	

### Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

#### CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
Acinus, Hyperplasia, Focal	(	(==)	1 (2%)	3 (6%)	
Salivary Glands Atrophy Vacuolization Cytoplasmic	(50)	(50) 1 (2%) 1 (2%)	(50)	(50)	
Stomach, Forestomach Edema	(50) 1 (2%)	(50) 3 (6%)	(50) 2 (4%)	(50) 3 (6%)	
Inflammation, Chronic Active Ulcer	1 (2%) 2 (4%)	2 (4%)	2 (4%)	2 (4%)	
Epithelium, Hyperplasia Stomach, Glandular Edema	3 (6%) (50)	1 (2%) (50)	2 (4%) (50)	6 (12%) (50) 2 (4%)	
Erosion Ulcer Epithelium, Hyperplasia	1 (2%)	2 (4%)	2 (4%)	3 (6%) 1 (2%) 1 (2%)	
Tongue Hyperkeratosis	(1)	2 (4%) (0)	(1)	(1) 1 (100%)	
Epithelium, Hyperplasia	1 (100%)			1 (10070)	
CARDIOVASCULAR SYSTEM					
Heart Cardiomyopathy Thrombosis	(50) 46 (92%)	(50) 43 (86%) 2 (4%)	(50) 43 (86%) 1 (2%)	(50) 48 (96%) 1 (2%)	
ENDOCRINE SYSTEM					
Adrenal Cortex Accessory Adrenal Cortical Nodule Angiectasis	(50) 1 (2%) 1 (2%)	(50) 3 (6%)	(50) 1 (2%)	(50)	
Degeneration, Fatty Hematopoietic Cell Proliferation	15 (30%)	20 (40%) 2 (4%)	24 (48%)	13 (26%) 1 (2%)	
Hyperplasia, Focal Hypertrophy, Focal Hypertrophy, Diffuse Necrosis	1 (2%) 12 (24%)	4 (8%) 10 (20%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	1 (2%) 9 (18%)	2 (4%) 2 (4%)	
Capsule, Developmental Malformation Adrenal Medulla Hyperplasia	(50) 1 (2%)	(50) (2%) 1 (2%)	(50) 3 (6%)	(50) 2 (4%)	
Islets, Pancreatic Hyperplasia	(50)	(50) 4 (8%)	(50) 1 (2%)	(50) 11 (22%)	
Parathyroid Gland Hyperplasia	(49)	(48)	(48)	(45) 1 (2%)	
Pituitary Gland Pars Distalis, Angiectasis	(50)	(50) 1 (2%)	(49) 1 (2%)	(50) 3 (6%)	

### Test Type: CHRONIC

#### Route: GAVAGE

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

#### Androstenedione

#### CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
Pars Distalis, Cyst	18 (36%)	12 (24%)	14 (29%)	13 (26%)	
Pars Distalis, Hyperplasia, Focal	20 (40%)	20 (40%)	14 (29%)	19 (38%)́	
Pars Intermedia, Angiectasis	1 (2%)				
Rathke's Cleft, Cyst	3 (6%)	1 (2%)	4 (8%)		
Thyroid Gland	(50)	(50)	(50)	(50)	
Ultimobranchial Cyst			2 (4%)	1 (2%)	
C-cell, Hyperplasia	27 (54%)	33 (66%)	24 (48%)	25 (50%)	
Follicle, Cyst		1 (2%)	2 (4%)	1 (2%)	
Follicular Cell, Hyperplasia	1 (2%)				

None

### **GENITAL SYSTEM**

Clitoral Gland Cyst Hyperplasia Inflammation, Suppurative Inflammation, Chronic Ovary Angiectasis Cyst Infiltration Cellular, Histiocyte Bursa, Dilatation Corpus Luteum, Hyperplasia Follicle, Cyst Interstitial Cell, Cyst Uterus Decidual Reaction Hemorrhage Hyperplasia, Cystic Inflammation, Suppurative Thrombosis Epithelium, Hyperplasia	(50) 6 (12%) 3 (6%) 1 (2%) 23 (46%) (50) 3 (6%) 6 (12%) (50) 9 (18%) 1 (2%)	(50) 8 (16%) 4 (8%) 26 (52%) (50) 5 (10%) 6 (12%) 1 (2%) 1 (2%) 1 (2%) 1 (2%)	(50) 8 (16%) 1 (2%) 18 (36%) (50) 2 (4%) 2 (4%) (50) 1 (2%) 1 (2%) 1 (2%) 11 (22%) 2 (4%)	(50) 4 (8%) 3 (6%) 1 (2%) 24 (48%) (50) 1 (2%) 1 (2%) 1 (2%) 6 (12%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 1 (2%) 14 (28%)	
HEMATOPOIETIC SYSTEM Bone Marrow	(50)	(50)	(50)	(50)	
Atrophy Hyperplasia Thrombosis	3 (6%)	(30) 1 (2%) 6 (12%) 1 (2%)	(30) 1 (2%) 5 (10%)	1 (2%)	

### Test Type: CHRONIC

Route: GAVAGE

Species/Strain: RATS/F 344

### P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

#### CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
Lymph Node	(5)	(10)	(16)	(10)	
Congestion			1 (6%)		
Deep Cervical, Ectasia			1 (6%)		
Deep Cervical, Necrosis	1 (20%)				
Mediastinal, Ectasia		2 (20%)	1 (6%)		
Mediastinal, Hemorrhage		3 (30%)	1 (6%)	1 (10%)	
Mediastinal, Hyperplasia, Lymphoid	2 (40%)	2 (20%)	3 (19%)		
Mediastinal, Infiltration Cellular, Mast Cell	1 (20%)				
Mediastinal, Pigmentation	1 (20%)				
Pancreatic, Ectasia			1 (6%)		
Pancreatic, Hemorrhage	1 (20%)	2 (20%)	3 (19%)	2 (20%)	
Pancreatic, Hyperplasia, Histiocytic			1 (6%)		
Pancreatic, Pigmentation				1 (10%)	
Lymph Node, Mandibular	(0)	(0)	(0)	(1)	
Lymph Node, Mesenteric	(50)	(50)	(49)	(50)	
Ectasia	2 (4%)		3 (6%)	4 (8%)	
Hemorrhage			1 (2%)		
Hyperplasia, Histiocytic	29 (58%)	34 (68%)	24 (49%)	19 (38%)	
Hyperplasia, Lymphoid		1 (2%)	1 (2%)	1 (2%)	
Pigmentation	1 (2%)		2 (4%)		
Spleen	(50)	(49)	(50)	(50)	
Fibrosis			1 (2%)		
Hematopoietic Cell Proliferation	5 (10%)	3 (6%)	6 (12%)	2 (4%)	
Hemorrhage		1 (2%)	1 (2%)	1 (2%)	
Hyperplasia, Lymphoid				1 (2%)	
Infiltration Cellular, Mixed Cell				1 (2%)	
Pigmentation	43 (86%)	44 (90%)	39 (78%)	36 (72%)	
Lymphoid Follicle, Hyperplasia	1 (2%)	2 (4%)	3 (6%)	11 (22%)	
Thymus	(50)	(50)	(49)	(50)	
Atrophy				1 (2%)	
Hemorrhage		1 (2%)			
ITEGUMENTARY SYSTEM					
Mammary Gland	(50)	(50)	(50)	(50)	
Cyst	15 (30%)	3 (6%)	9 (18%)	3 (6%)	
Hyperplasia	48 (96%)	40 (80%)	35 (70%)	23 (46%)	
Inflammation, Suppurative			,	1 (2%)	
Skin	(50)	(50)	(50)	(50)	
Cyst Epithelial Inclusion	(00)	1 (2%)	(00)	1 (2%)	
Hyperkeratosis		1 (2%)		2 (4%)	

MUSCULOSKELETAL SYSTEM

TDMS No. 99024 - 07 Test Type: CHRONIC Route: GAVAGE Species/Strain: RATS/F 344	P03: INCIDENCE	Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI			
FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
Bone Hyperostosis Skeletal Muscle Inflammation, Chronic	(50) (0)	(50) (1) 1 (100%)	(50) (0)	(50) 1 (2%) (0)	
NERVOUS SYSTEM					
Brain Compression Hemorrhage Hydrocephalus	(50) 6 (12%) 1 (2%) 1 (2%)	(50) 10 (20%) 1 (2%)	(50) 4 (8%)	(50) 5 (10%) 1 (2%)	
RESPIRATORY SYSTEM					
Lung Congestion Emphysema Hemorrhage	(50)	(50) 1 (2%) 1 (2%) 1 (2%)	(50)	(50)	
Infiltration Cellular, Histiocyte Inflammation, Chronic Pigmentation Alveolar Epithelium, Hyperplasia	31 (62%) 1 (2%)	37 (74%) 1 (2%) 1 (2%) 13 (26%)	26 (52%) 1 (2%)	27 (54%) 1 (2%)	
Artery, Hypertrophy Nose Foreign Body Inflammation, Suppurative	12 (24%) (50) 6 (12%) 3 (6%)	1 (2%) (50) 4 (8%) 2 (4%)	11 (22%) (50) 6 (12%) 3 (6%)	10 (20%) (50) 3 (6%)	
Inflammation, Chronic Respiratory Epithelium, Hyperplasia	3 (6%) 7 (14%)	2 (4%) 8 (16%)	1 (2%) 1 (2%)	1 (2%)	
SPECIAL SENSES SYSTEM					
Ear Inflammation, Suppurative Eye	(0) (49)	(1) 1 (100%) (48) 1 (2%)	(0) (47)	(0) (49)	
Atrophy Cataract Cornea, Inflammation, Chronic Retina, Degeneration	1 (2%) 3 (6%)	1 (2%) 1 (2%) 1 (2%)	3 (6%)	1 (2%) 1 (2%)	
Sclera, Metaplasia, Osseous Harderian Gland Infiltration Cellular, Lymphocyte Zymbal's Gland	1 (2%) (50) (0)	(50) (0)	1 (2%) (50) 1 (2%) (1)	(50) (0)	

Species/Strain: RATS/F 344

### Test Type: CHRONIC

Route: GAVAGE

# P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE(a)

Androstenedione

#### CAS Number: 63-05-8

Date Report Requested: 08/08/2008 Time Report Requested: 08:20:33 First Dose M/F: 02/03/03 / 02/03/03 Lab: SRI

FISCHER 344 RATS FEMALE	0 MG/KG	10 MG/KG	20 MG/KG	50 MG/KG	
JRINARY SYSTEM					
Kidney	(50)	(49)	(50)	(50)	
Cyst	2 (4%)	4 (00/)	4 (00/)	1 (2%)	
Glomerulosclerosis Infarct	2 (4%)	1 (2%)	1 (2%) 1 (2%)		
Nephropathy	48 (96%)	44 (90%)	43 (86%)	43 (86%)	
Renal Tubule, Accumulation, Hyaline Droplet	3 (6%)			2 (4%)	
Renal Tubule, Necrosis	- ()			1 (2%)	
Renal Tubule, Pigmentation	1 (2%)		2 (4%)	3 (6%)	
Renal Tubule, Vacuolization Cytoplasmic		1 (2%)			
Urinary Bladder	(50)	(50)	(50)	(50)	

\*\*\* END OF REPORT \*\*\*